These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30001857)

  • 1. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?
    Desmet S; Verhaegen J; Van Ranst M; Peetermans W; Lagrou K
    Lancet Infect Dis; 2018 Aug; 18(8):830-831. PubMed ID: 30001857
    [No Abstract]   [Full Text] [Related]  

  • 2. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
    Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme.
    Wouters I; Van Heirstraeten L; Desmet S; Blaizot S; Verhaegen J; Goossens H; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2018 Jan; 36(1):15-22. PubMed ID: 29180027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Euro Surveill; 2017 Mar; 22(10):. PubMed ID: 28300529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Imöhl M
    PLoS One; 2015; 10(7):e0131494. PubMed ID: 26132078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
    PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland.
    Allemann A; Frey PM; Brugger SD; Hilty M
    Vaccine; 2017 Apr; 35(15):1946-1953. PubMed ID: 28279564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
    Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nationwide study on the impact of pneumococcal conjugate vaccination on antibiotic use and ventilation tube insertion in Denmark 2000-2014.
    Howitz MF; Harboe ZB; Ingels H; Valentiner-Branth P; Mølbak K; Djurhuus BD
    Vaccine; 2017 Oct; 35(43):5858-5863. PubMed ID: 28928078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive Pneumococcal Disease Surveillance, 1 October to 31 December 2016.
    Pennington K;
    Commun Dis Intell Q Rep; 2017 Mar; 41(1):E114-E119. PubMed ID: 28385146
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR).
    Abu Seir R; Azmi K; Hamdan A; Namouz H; Jaar F; Jaber H; Rubin C; Doron D; Rahav G; Abdeen Z; Regev-Yochay G
    PLoS One; 2018; 13(11):e0206927. PubMed ID: 30418989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.
    Chen JJ; Yuan L; Huang Z; Shi NM; Zhao YL; Xia SL; Li GH; Li RC; Li YP; Yang SY; Xia JL
    BMJ Open; 2016 Oct; 6(10):e012488. PubMed ID: 27798013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cohort study of the impact and acquisition of naspharyngeal carriage of Streptococcus pneumoniae during the Hajj.
    Memish ZA; Al-Tawfiq JA; Almasri M; Akkad N; Yezli S; Turkestani A; van der Linden M; Assiri A
    Travel Med Infect Dis; 2016; 14(3):242-7. PubMed ID: 27189624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.